lynparza
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
February 26, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer
January 15, 2018Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma
The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
AZ’s Lynparza improves survival and maintains quality of life against ovarian cancer
June 2, 2017Medical Communications, Research and Development AstraZeneca, lynparza
New Phase 3 trial data has found that AstraZeneca’s Lynparza (olaparib) provides sustained quality of life (QoL) and improved progression-free …
AZ reveals compelling PhIII data for ovarian cancer treatment
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials
May 18, 2016Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III
AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
AZ’s Lynparza gets prostate cancer breakthrough status
January 28, 2016Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer
AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
Latest content
Dermatology leader Doncker is new Onicor CEO
